Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr Singer on the Safety of Perioperative Nivolumab and Cabozantinib in RCC

May 18th 2023

Eric A. Singer, MD, discusses the safety of perioperative nivolumab and cabozantinib in patients with metastatic clear cell renal cell carcinoma.

Dr Tsao on the Investigation of Cabozantinib With Nivolumab and Ipilimumab in RCC

May 16th 2023

Che-Kai Tsao, MD, discusses the investigation of cabozantinib in combination with nivolumab and ipilimumab in patients with renal cell carcinoma.

Dr Galsky on the Importance of Improved Disease Classification Within Non–Clear Cell RCC

May 15th 2023

Matthew Galsky, MD, discusses the importance of developing specific disease classifications within non–clear cell renal cell carcinomas.

Dr Ryan on the Role of Adjuvant Therapy in RCC

May 12th 2023

Christopher W. Ryan, MD, discusses the role of adjuvant therapy for patients with renal cell carcinoma.

Hsp70 Inhibition Could Help Overcome Belzutifan Resistance in VHL Disease–Associated ccRCC

May 12th 2023

Michael Basin, MD, discusses the rationale for the preclinical investigation of belzutifan resistance in ccRCC cell lines, the next steps for this research, and the potential implications for combining Hsp70 inhibition with a HIF2α inhibitor.

Dr Tsao on First-line Treatment Approaches in Clear Cell RCC

May 11th 2023

Che-Kai Tsao, MD, discusses first-line treatment approaches for patients with clear cell renal cell carcinoma.

Dr Galsky on the Need for Novel Drug Classes and Non–Cross-Resistant Options in mRCC

May 8th 2023

Matthew Galsky, MD, explains how the development of novel drug classes and therapeutic combinations could address unmet needs in patients with metastatic renal cell carcinoma.

Dr Zhang on Sintilimab Plus Axitinib in FH-Deficient RCC

May 3rd 2023

Xingming Zhang discusses efficacy, safety, and quality of life findings from a phase 2 trial investigating the combination of sintilimab and axitinib in patients with fumarate hydratase–deficient renal cell carcinoma.

89Zr-DFO-girentuximab May Improve Identification, Risk Stratification of Renal Tumors

May 2nd 2023

Findings from the phase 3 ZIRCON trial showed that imaging with 89Zr-DFO-girentuximab could improve the identification and risk stratification of patients with renal tumors.

Key Trial Updates Confirm and Clarify Treatment Approaches Across Genitourinary Cancers

May 2nd 2023

Matthew Galsky, MD, highlights updates in metastatic urothelial cancer treatment, as well as the evolution of PARP inhibitors and the optimal use of intensified triplet therapy in prostate cancer.

Dr Daneschmand on Data From SunRISe-1 With TAR-200 and Cetrelimab in BCG-Unresponsive NMIBC

May 1st 2023

Sia Daneshmand MD, discusses preliminary results from the phase 2 SunRISe-1 trial (NCT04640623) in patients with non–muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guérin.

Dr Saad on PSA Response and Time to PSA Progression With Abiraterone Acetate and Olaparib in mCRPC

May 1st 2023

Fred Saad, MD, FRCS, discusses prostate-specific antigen (PSA) response and time to PSA progression with the combination of abiraterone acetate and olaparib in patients with metastatic castration-resistant prostate cancer.

High BMI Associated With Longer OS in Patients With RCC Undergoing Nephrectomy

April 30th 2023

A high body mass index was linked with improved overall survival in patients with renal cell carcinoma undergoing radical nephrectomy.

Dr Basin on Pharmacological Inhibition of Hsp70 in Belzutifan-Resistant RCC

April 28th 2023

Michael Basin, MD, discusses how the pharmacological inhibition of the molecular chaperone Hsp70 overcomes belzutifan resistance in clear cell renal cell carcinoma.

Dr Hasanov on Actionable Immune-Resistance Targets in RCC With Brain Metastases

April 28th 2023

Elshad Hasanov, MD, PhD, discusses actionable immune-resistance targets in patients with renal cell carcinoma with brain metastases.

Cabozantinib/Atezolizumab Combo Provides Durable Benefit in Non–clear Cell RCC, Across Histological Subtypes

April 27th 2023

Bradley A. McGregor, MD, discusses the clinical significance of the updated COSMIC-021 data, how these findings support the continued investigation of IO/TKI combinations in non–clear cell renal cell carcinoma, and other efforts underway to better care for patients with varying histological subtypes of the disease.

Toripalimab Plus Axitinib Meets PFS End Point in Unresectable or Distant Metastatic RCC

April 27th 2023

The combination of toripalimab and axitinib improved progression-free survival over single-agent sunitinib when used as first-line treatment in patients with intermediate to high risk, unresectable or distant metastatic renal cell carcinoma.

Nivolumab/Ipilimumab Prolongs Survival in Metastatic Clear Cell RCC Subsets

April 27th 2023

Treatment with nivolumab plus ipilimumab and a subsequent TKI was effective in patients with metastatic clear cell renal cell carcinoma.

Genetic Counseling for Patients with Non-Clear Cell RCC

April 26th 2023

The panel closes their discussion with a look at the standards for genetic counseling for patients with non-clear cell RCC.

Best Approaches and Emerging Data in the Treatment of Non-Clear Cell RCC

April 26th 2023

The panel discusses the best approaches to treating patients with non-clear cell RCC.